Stereotaxis, Inc. 10-Q Summary: Quarter Ended September 30, 2008
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Stereotaxis, Inc., a developer of magnetic navigation systems for interventional cardiology, for the period ended September 30, 2008. The company designs the NIOBE system for catheter navigation and the ODYSSEY information management system. The filing covers the three and nine months ended September 30, 2008, compared to the same periods in 2007.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2008 |
|---|---|---|
| Total Revenue | $10.55 million | $28.24 million |
| Gross Margin | $6.91 million (65.5%) | $17.99 million (63.7%) |
| Operating Loss | $(9.20 million) | $(34.63 million) |
| Net Loss | $(10.07 million) | $(36.39 million) |
| Cash and Equivalents | $19.78 million | $19.78 million (Balance Sheet) |
| Working Capital | $2.87 million | N/A |
| Total Debt | $33.43 million | $33.43 million (Balance Sheet) |
| Current Ratio | 1.07x | N/A |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 12% in the quarter and 3% in the nine-month period compared to 2007. System sales revenue dropped 22% (quarter) and 13% (nine months) due to fewer NIOBE system installations (6 vs. 9 in the quarter; 18 vs. 20 in the nine months). Conversely, revenue from disposables, service, and accessories increased 25% (quarter) and 30% (nine months) driven by a larger installed base.
- Expense Reductions: Research and Development (R&D) expenses decreased significantly by 35% in the quarter and 29% in the nine-month period, attributed to reduced costs for new product introductions. Sales and marketing expenses decreased 9% in the quarter but increased 12% over the nine months due to expanded operations.
- Debt Increase: Total debt increased from $7.0 million at year-end 2007 to $33.4 million at September 30, 2008. This includes a $15.0 million long-term obligation to Biosense Webster (classified as debt) and increased utilization of revolving credit facilities.
- Liquidity Position: Working capital decreased from $21.9 million at December 31, 2007, to approximately $2.9 million at September 30, 2008, reflecting cash burn and debt utilization.
Outlook, Risks, and Management Commentary
- Liquidity and Capital Resources: Management expects negative cash flow from operations for the succeeding 12 months. The company relies on existing cash, credit facilities, and the Biosense Webster agreement to fund operations. While they anticipate renewing their bank facility (maturing March 2009), there is no assurance of terms or availability.
- Debt Covenants and Triggers: The Biosense Webster agreement includes an "Accelerating Recoupment Event" clause. If the company raises $50 million in equity financing, fails to make supplemental payments, or undergoes a change of control, the debt becomes immediately due. Quarterly supplemental payments to Biosense Webster are required starting May 15, 2010.
- Investment Risks: The company holds $500,000 in auction rate securities (ARS). Due to market illiquidity, these were impaired by $32,000 in 2008. However, a subsequent event in October 2008 indicated an agreement to repurchase the security at par, potentially recovering the impairment.
- Backlog: Purchase orders and commitments for systems were approximately $75 million as of September 30, 2008, though management notes these are subject to contingencies and cancellation.
Investor Verification Checklist
- Debt Maturity: Verify the status of the $13.2 million revolving credit line maturing in March 2009 and the $15.0 million Biosense Webster obligation.
- Working Capital Trend: Monitor the sharp decline in working capital from $21.9M to $2.9M and the company's ability to maintain the $5.0 million tangible net worth covenant.
- Revenue Mix: Assess the sustainability of the shift from high-margin system sales to recurring disposable/service revenue as system installation rates decline.
- ARS Liquidity: Confirm the final settlement of the auction rate security repurchase to ensure the $32,000 impairment is fully reversed.
- Accelerating Recoupment: Evaluate the risk of triggering the Biosense Webster debt acceleration clause via future equity financing or missed payments.